Studies continue to put a harsh light on proton pump inhibitors (PPIs), which are medications used...READ MORE
FDA investigating link between Parkinson’s drug Stalevo, heart disease
The U.S. Food and Drug Administration (FDA) has announced an investigation into whether the drug Stalevo, which is used to treat Parkinson’s disease, may increase elderly patients’ risk of heart attack and stroke. The FDA encourages patients taking the drug to talk to their physicians about their risk of cardiovascular disease.
For the full story, go to the Los Angeles Times.